Search company, investor...

Auris Medical

aurismedical.com

Founded Year

2003

Stage

IPO | IPO

Total Raised

$66.74M

Date of IPO

8/6/2014

Market Cap

0.01B

About Auris Medical

Auris Medical is dedicated to the development of pharmaceutical therapies to prevent or treat severe inner ear disorders. The company aims to protect people against hearing loss from various sources and to finally bring relief to people suffering from tinnitus.

Headquarters Location

Falknerstrasse 4

Basel, CH-4001,

Switzerland

+41 (0)61 201 13 50

Missing: Auris Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Auris Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Auris Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Auris Medical is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Auris Medical Patents

Auris Medical has filed 1 patent.

The 3 most popular patent topics include:

  • Audiology
  • Auditory system
  • Hearing
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/22/2019

4/6/2021

NMDA receptor antagonists, Auditory system, Audiology, Hearing, Amines

Grant

Application Date

7/22/2019

Grant Date

4/6/2021

Title

Related Topics

NMDA receptor antagonists, Auditory system, Audiology, Hearing, Amines

Status

Grant

Latest Auris Medical News

Auris Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Auris Medical Rank

Auris Medical Frequently Asked Questions (FAQ)

  • When was Auris Medical founded?

    Auris Medical was founded in 2003.

  • Where is Auris Medical's headquarters?

    Auris Medical's headquarters is located at Falknerstrasse 4, Basel.

  • What is Auris Medical's latest funding round?

    Auris Medical's latest funding round is IPO.

  • How much did Auris Medical raise?

    Auris Medical raised a total of $66.74M.

  • Who are the investors of Auris Medical?

    Investors of Auris Medical include Sofinnova Ventures, Sofinnova Partners, AGF Private Equity, Lacuna, Zurcher Kantonalbank and 3 more.

  • Who are Auris Medical's competitors?

    Competitors of Auris Medical include Intarcia Therapeutics, Bellus Health, Neuronascent, NeuroTherapeutics Pharma, Cytochroma and 13 more.

Compare Auris Medical to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

V
Valens Therapeutics

Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

O
Osteologix

Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

N
NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

P
Phytomedics

Phytomedics is a biopharmaceutical company based in New Jersey with a broad portfolio of novel compounds for chronic diseases. The lead compound is in clinical development and has shown extraordinary results in clinical trials for the treatment of auto immune disorders like rheumatoid arthritis. The company's platform technology is the basis of their large portfolio of novel therapeutic compounds.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.